Clinical Trial Update: Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

A randomized Phase 1/2 open-label trial evaluating PR-104 in combination with sorafenib in patients with advanced hepatocellular carcinoma; the study was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PR-104
• Sorafenib (Sorafenib)

Snippet

Sponsor: Proacta, Incorporated | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2013-08-23